Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 3Terminated 1Recruiting 1

Sponsor Class

OTHER 40INDUSTRY 5NIH 3NETWORK 2UNKNOWN 1

Study Type

Interventional 3Observational 2

Sponsor

Cancer Type

Thoracic 7Genitourinary 7Breast 5Tumor-Agnostic 4CNS 4Other solid neoplasm 3Head & Neck 3Dermatologic 3Gynecologic 2Plasma cell 1Other hematologic neoplasm 1Other 1Myeloid 1Lymphoid 1Gastrointestinal 1

Conditions

Breast Neoplasms 4Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Melanoma 1Head and Neck Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

Trastuzumab 242Paclitaxel 223Fulvestrant 196Capecitabine 182Docetaxel 164Letrozole 142pembrolizumab 115Carboplatin 100exemestane 98Gemcitabine 98Cyclophosphamide 92palbociclib 86Anastrozole 83pertuzumab 78Lapatinib 73Bevacizumab 71ribociclib 68130-nm albumin-bound paclitaxel 66abemaciclib 59eribulin 58Doxorubicin 55Vinorelbine 51Injections 47Ado-Trastuzumab Emtansine 47Tamoxifen 45Everolimus 44Albumin-Bound Paclitaxel 44atezolizumab 35trastuzumab deruxtecan 34Nivolumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Therapeutics × Breast × Clear all
NCT07020117 2026-04-21

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

Aktis Oncology, Inc.

Phase 1 Recruiting
150 enrolled
BreastHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Triple Negative Breast Neoplasms

NCT00828854 2022-06-30

Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing

Syndax Pharmaceuticals

Phase 2 Completed
27 enrolled 13 charts
Breast

Breast Neoplasms

NCT01357863 2018-09-14

(TYCO1)

GlaxoSmithKline

Terminated
3 enrolled
Breast

Breast Neoplasms, Neoplasms

NCT01160094 2016-03-28

TYCO

Novartis

Completed
288 enrolled
Breast

Breast Neoplasms, Neoplasms

NCT00827177 2014-01-24

Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1 Completed
87 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡